Propisergide (INNTooltip International Nonproprietary Name), also known as ergalgin or as N-methylergometrine or 1-methylergometrine, is a serotonin receptor modulator and antimigraine agent of the ergoline and lysergamide families which was never marketed.[1][2][3][4] It is the 1-methyl derivative of ergometrine (ergonovine) and is a close analogue of methylergonovine and methysergide.[5] The drug was first described in the literature by 1962[6] and then further around 1980 and after.[4][7][8]

References

  1. ^ Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. ISBN 978-1-4757-2085-3. Retrieved 13 March 2025.
  2. ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Taylor & Francis. ISBN 978-0-412-46630-4. Retrieved 13 March 2025.
  3. ^ Waldman M, Fraczkiewicz R, Clark RD (September 2015). "Tales from the war on error: the art and science of curating QSAR data". Journal of Computer-Aided Molecular Design. 29 (9): 897–910. Bibcode:2015JCAMD..29..897W. doi:10.1007/s10822-015-9865-0. PMID 26290258.
  4. ^ a b Oelszner W (1980). "Displacement of specific serotonin and lysergic acid diethylamide binding by Ergalgin, a new antiserotonin drug". Acta Biologica et Medica Germanica. 39 (8–9): 897–901. PMID 7282219.
  5. ^ "Propisergide". PubChem. U.S. National Library of Medicine. Retrieved 13 March 2025.
  6. ^ World Health Organization (1962). Cumulative List of Proposed International Non-proprietary Names for Pharmaceutical Preparations. 1962-. World Health Organization. ISBN 978-92-4-056013-0. Retrieved 13 March 2025.
  7. ^ Bartsch R, Nowak R (January 1979). "Pharmacological Evaluation of a New Ergolin Derivative (Ergalgin)". Die Pharmazie. 34 (5–6). Eschborn, Germany: Govi-Verlag Pharmazeutischer GmbH: 358.
  8. ^ Harhammer R, Morgenstern R, Ott T (1992). "Pharmacological Effects of Ergalgin, a Potent Antagonist at Central and Peripheral 5-Ht (2) Receptors". Biogenic Amines. 8 (3–4): 267–275.
No tags for this post.